T. Rowe Price Associates »

Black Diamond Therapeutics shares owned by T. Rowe Price Associates

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by T. Rowe Price Associates from 13F filings

Historical chart of T. Rowe Price Associates investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by T. Rowe Price Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by T. Rowe Price Associates

Quarter filed Position value Share count Share price at filing
2024-06-30 $3.8M 813k 4.69
2020-09-30 $817k 27k 30.23

More positions owned by T. Rowe Price Associates

Microsoft Corp Comm Stk (MSFT)
Nvidia Corporation Comm Stk (NVDA)
Apple Comm Stk (AAPL)
Amazon Comm Stk (AMZN)
Meta Platforms Comm Stk (META)
Eli Lilly & Co Comm Stk (LLY)
Alphabet Comm Stk (GOOGL)
Alphabet Comm Stk (GOOG)
Unitedhealth Group Comm Stk (UNH)
Visa Comm Stk (V)
Mastercard Incorporated Comm Stk (MA)
Netflix Comm Stk (NFLX)
Intuitive Surgical Comm Stk (ISRG)
Elevance Health Comm Stk (ELV)
Schwab Charles Corp Comm Stk (SCHW)

View all positions for T. Rowe Price Associates

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
Bellevue Group
NEA Management Company
BlackRock
Vanguard Group
Vestal Point Capital
Tang Capital Management
Millennium Management
Artal Group
Geode Capital Management
T. Rowe Price Associates
Invesco
Kennedy Capital Management
State Street Corporation
Stempoint Capital

View all funds holding Black Diamond Therapeutics